NCT00441571View on ClinicalTrials.gov

Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2007

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

177Lu-CYT-500

Trial Locations (1)

10021

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
lead

Cytogen Corporation

INDUSTRY